A bispecific peptide LFOP targeting PD-1/PD-L1 and LAG-3/FGL1 has the ability to activate T cells and increase tumor infiltration with T lymphocytes, and the effect is synergistic with irradiation, amplifying the immune response [28,29]. The gene discussed is PDCD1; the disease is neoplasm.